Colder Drugs Will Prevail - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Colder Drugs Will Prevail
An expanding number of products and services plug gaps in the cold chain. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 33, Issue 8

Refrigerator monitors

An automated, paperless system closes a cold-chain gap by monitoring refrigerator temperature in pharmacies and dispensing areas operated by the South Eastern Health and Social Care Trust in Northern Ireland. Wireless sensors regularly check the temperature of refrigerators where vaccines, erythropoietin, and chemotherapy drugs are stored. Deviations from preset temperature parameters trigger audiovisual alarms onsite, as well as text messages and emails to key staff members. With the system, the Trust will be able to develop an archive of historical temperature data and corrective actions to form an audit trail (Wireless to Web, Kelsius, Belfast). To provide full traceability, the Trust also uses portable data loggers to monitor temperature-sensitive products during transit to primary-care locations (Portable data loggers, Kelsius).

Another diagnostic toolkit monitors refrigerators and freezers to provide early warnings if temperatures deviate from norms and also serves as a predictive-maintenance tool. Monitoring labels are activated and positioned at various points inside the refrigerator or freezer and collect data at intervals even during a power outage. Data are downloaded through a wireless reader for review and transfer to a personal computer, where they can be stored permanently and analyzed (Ultra TK diagnostic tool kit, PakSense, Boise, ID).

Conditions in refrigerated truck trailers can be checked through a system that automates remote monitoring of their internal temperatures as well as the status of the refrigeration units and fuel levels. Based on a mounted passive RFID tag, the system transmits data in real time, eliminates repeated manual checks, and can be configured to provide alarms if temperature or fuel levels drift outside predefined thresholds (Yard Hound Reefer yard-management software, PINC Solutions, Berkeley, CA).

On the horizon

The pharmaceutical cold chain remains largely self-regulated. "Everyone puts together their own protocol," says Etienne P. Snollaerts, chief executive officer of Coldpack.

Many packaging engineers take a conservative stance and overengineer their protective packaging, he notes. For example, many protocols specify a 2–8 C temperature range. This narrow window can be challenging to meet and can increase costs if it requires additional refrigerant or insulation. Although it's generally imperative to prevent freezing, many products suffer no loss of quality at temperatures slightly above 8 C, thus making a temperature range wider than 2–8 C feasible in some cases. "In fact," says Snollaerts, "up to 16 C is acceptable for vaccines, according to WHO."

The adoption of less stringent protocols may be supported by work underway on standards. In the United States, a division of the Parenteral Drug Association is working with ISTA to develop test profiles for the cold chain. Parameters include minimum load, maximum load, and orientation. If successful, "a 96-h box would meet a standard set of guidelines," explains Lindquist. He predicts the groups will publish a finalized document before the end of 2010 and that it eventually will serve as the basis for mandates by the US Food and Drug Administration or the US Pharmacopeia.

He also expects a rising level of regulatory interest in enforcing controlled room-temperature conditions. Maintaining products at controlled room temperature has been difficult because of a lack of sufficient protective packaging. This situation is changing as new conductive systems are marketed.

Another change likely to affect cold-chain packaging is the phase-out of disposable packaging. It's already occurring in Europe, Japan, and China, and Lindquist predicts that similar requirements eventually will be adopted in the US.

"Convincing the pharmaceutical industry to change takes time, but we're sure it's coming," says Snollaerts.

Hallie Forcinio is Pharmaceutical Technology's Packaging Forum editor, 4708 Morningside Drive, Cleveland, OH 44109, tel. 216.351.5824, fax 216.351.5684,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here